« Return to News | CROs/Service Providers

WorldCare Clinical launches oncology imaging studies service

Monday, August 12, 2013 01:14 PM

CRO WorldCare Clinical (WCC) has launched a service that enables simultaneous capture and analysis of both standard tumor assessments, including Response Evaluation Criteria in Solid Tumors (RECIST) and the immune-related response criteria (irRC). WCC’s method has been validated and is being used to evaluate new immune-related treatments.  

WCC developed its combination case report form (CRF) to facilitate concurrent tumor assessments using both methods. The service was designed for sponsors developing immunotherapeutic agents that want to analyze performance using irRC, but also want to capture RECIST responses until the newer irRC becomes more established.

“Employing a combined approach to tumor assessment allows for time savings when performing the imaging interpretation, resulting in a significant cost savings to the sponsor,” said Richard Walovitch, Ph.D., president of WCC. “Using our combination CRF, we’re able to programmatically calculate the response using the criteria of both methods.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.